These compounds are specific inhibitors of osteoclastic activity and may significantly reduce skeletal complications, thereby sustaining the quality of life of cancer patients.
Finally, patients may also be receiving ZA for metastatic bone disease, to reduce skeletal morbidity and pain (Rosen et al, 2001).
These patients may also be receiving the bisphosphonate, zoledronic acid (ZA) to prevent bone loss or reduce skeletal morbidity in the setting of advanced disease.
While breast cancer therapy focuses largely on tumor cells, agents that target bone may not only reduce skeletal-related events but also sensitize the tumor to conventional therapies.
Treatment with vitamin D may have exerted an attenuating effect on the capillaroscopic findings, because improving hyperparathyroidism may reduce the release of skeletal muscle minerals and reduce their participation in the process of vascular and coronary calcification [ 22].
Therefore, directly inhibiting lipid peroxidation of the myocyte by free radicals in skeletal muscles may reduce the secondary edema and inflammatory infiltration incidence of oxidative stress on tissues.
This finding does not necessarily present a contradiction: a shift from oxidative to glycolytic pathway metabolism in skeletal muscle tissue may reduce demand for oxygen as an alternative to capillary growth.
Future studies should further examine this differential response of IMAT to exercise interventions, as well as other exercise interventions that may reduce the rate of fatty infiltration of skeletal muscle.
Bisphosphonates reduce skeletal-related events (SREs) in patients with skeletal metastasis [ 9- 13].
Some mechanisms have been proposed to explain how exercise training may reduce chronic low-grade inflammation in MS. It is known that as well as the adipose tissue, the working skeletal muscle is a potential source of cytokines.
